NCT03439657 - Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older | Biotech Hunter

Enrollment

913

Participants

Timeline

Start Date

April 12, 2018

Primary Completion Date

May 6, 2019

Study Completion Date

March 3, 2020

Conditions

Herpes Zoster

Interventions

BIOLOGICAL

HZ/su vaccine GSK1437173A

2 doses of 0.5 mL of the vaccine in a 0,2 Months schedule. Administered by intramuscular injection into the deltoid muscle of the non-dominant arm.

BIOLOGICAL

Prevenar13

1 dose of 0.5 mL of the vaccine. Administered by intramuscular injection into the deltoid muscle of the dominant arm.

Trial Locations (13)

GSK Investigational Site, Tallinn

GSK Investigational Site, Salisbury

GSK Investigational Site, Spartanburg

GSK Investigational Site, Rakvere

GSK Investigational Site, Essen

GSK Investigational Site, Goch

GSK Investigational Site, Tartu

GSK Investigational Site, Mainz

GSK Investigational Site, Weinheim

GSK Investigational Site, Würzburg

GSK Investigational Site, Marlborough

GSK Investigational Site, Truro

GSK Investigational Site, Sherbrooke